References
- Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001 Nov 15; 345(20): 1465–72. doi: 10.1056/NEJMra010902.
- Medrek S, Safdar Z. Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. Methodist Debakey Cardiovasc J. 2016 Oct-Dec; 12(4): 195–198. doi: 10.14797/mdcj-12-4-195.
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl): D34–41. doi: 10.1016/j.jacc.2013.10.029.
- Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013 Feb; 41(2): 462–8. doi: 10.1183/09031936.00049312.
- Schweikert B, Pittrow D, Vizza CD, et al. Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. BMC Health Serv Res. 2014 Jun 9; 14: 246. doi: 10.1186/1472-6963-14-246.
- Lee JD, Burger CD, Delossantos GB, et al. A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Ann Am Thorac Soc. 2020 Dec; 17(12): 1576–1582. doi: 10.1513/AnnalsATS.202005-521OC.
- Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation. 2016 Mar 1; 133(9): 859–71. doi: 10.1161/CIRCULATIONAHA.115.016522.
- Kim NH, D’Armini AM, Grimminger F, et al. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart. 2017 Apr; 103(8): 599–606. doi: 10.1136/heartjnl-2016-309621.
- Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25; 369(4): 319–29. doi: 10.1056/NEJMoa1209657.
- Jais X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16; 52(25): 2127–34. doi: 10.1016/j.jacc.2008.08.059.
- Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017 Oct; 5(10): 785–794. doi: 10.1016/S2213-2600(17)30305-3.
- Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015 May; 45(5): 1293–302. doi: 10.1183/09031936.00087114.
- Kim
NH,
Delcroix
M,
Jais
X, et al. Chronic
thromboembolic pulmonary hypertension. Eur Respir
J. 2019
Jan
24; 53(1):
1801915 . doi: 10.1183/13993003.01915-2018. - Hoeper MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2015 Jun; 24(136): 272–82. doi: 10.1183/16000617.00001015.
- Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013; 218: 279–313. doi: 10.1007/978-3-642-38664-0_12.
- Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest. 2008 Aug; 134(2): 229–236. doi: 10.1378/chest.07-2681.
- Reesink HJ, Meijer RC, Lutter R, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006 Aug; 70(8): 1058–63. doi: 10.1253/circj.70.1058.
- Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9): 809–18. doi: 10.1056/NEJMoa1213917.
- Escribano-Subias
P,
Bendjenana
H,
Curtis
PS,
Lang
I, Vonk
Noordegraaf
A. Ambrisentan for
treatment of inoperable chronic thromboembolic pulmonary hypertension
(CTEPH). Pulm Circ. Apr-Jun
2019; 9(2):
2045894019846433 . doi: 10.1177/2045894019846433. - Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1; 347(5): 322–9. doi: 10.1056/NEJMoa020204.
- Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019 Mar; 7(3): 239–248. doi: 10.1016/S2213-2600(18)30367-9.
- Lang
I,
Meyer
BC,
Ogo
T, et al. Balloon
pulmonary angioplasty in chronic thromboembolic pulmonary
hypertension. Eur Respir Rev.
2017
Mar
29; 26(143):
160119 . doi: 10.1183/16000617.0119-2016. - Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009 Sep 29; 120(13): 1248–54. doi: 10.1161/CIRCULATIONAHA.109.865881.
- Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. 2003 Feb; 123(2): 338–43. doi: 10.1378/chest.123.2.338.
- Bresser P, Fedullo PFWR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004 Apr; 23(4): 595–600. doi: 10.1183/09031936.04.00020004.
- Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012 Dec; 5(6): 748–55. doi: 10.1161/CIRCINTERVENTIONS.112.971077.
DOI: https://doi.org/10.14797/ICHN7633 | Journal eISSN: 1947-6108
Language: English
Accepted on: Mar 25, 2021
Published on: Jul 1, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 Ryan Logue, Zeenat Safdar, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.